Business
Lucid Diagnostics Announces Positive Data from the First Prospective Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population
Prospective VA screening study demonstrates excellent EsoGuard sensitivity of 92.9% and negative predictive value of 98.6% compared to upper gastrointestinal
About this update from Lucid Diagnostics Inc.
[{"type":"text","content":"Prospective VA screening study demonstrates excellent EsoGuard sensitivity of 92.9% and negative predictive value of 98.6% compared to upper gastrointestinal endoscopy\nAuthors conclude that EsoGuard is a \"powerful screening tool\" for esophageal precancer and cancer\nNEW YORK, March 21, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) (\"Lucid\" or the \"Company\"), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ( \"PAVmed\"), today announced that investigators at the Louis Stokes Cleveland Veterans Affairs Medical Center, led by Katarina B. Greer, M.D.,M.S., Associate Professor of Medicine at Case Western Reserve University School of Medicine, have released data from a Department of Defense funded prospective clinical validation study of patients who met strict national society guideline criteria for esophageal precancer testing. The study demonstrated excellent performance of Lucid's EsoGuard® Esophageal DNA test for esophageal precancer detection and is the first to present such clinical validity data in a screening population. The manuscript entitled Non-endoscopic screening for Barrett's esophagus and Esophageal Adenocarcinoma in at risk Veterans is available on the leading health sciences preprint server, medRxiv, pending peer review and publication.\n\n \n \n \n \n \n \n\n \n\"We are grateful to Dr. Greer and her co-investigators for this sentinel contribution to the clinical evidence supporting EsoGuard esophageal precancer testing,\" said Victoria T. Lee, M.D., Lucid's Chief Medical Officer. \"Data from this clinical validation study, the first in an 'intended use' screening population, closely mirror EsoGuard performance data from two previously reported NCI-funded case-control clinical validation studies—the original multi-center study which first introduced the technology, and the recently completed BETRNet study whose results were posted as a preprint last year pending peer review and publication. Collectively, these three clinical validity studies demonstrate excellent EsoGuard sensitivity and negative predictive value, including unprecedented performance of a molecular diagnostic test in detecting a precancer. They strongly support EsoGuard's use as a widespread screening tool to prevent esophageal cancer through the...